Israel’s BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced the completion of a U.S. clinical study, conducted by Ora, Inc. Andover, MA, designed to compare widely used benchmark tests for dry eye with its TeaRx diagnostic parameters that test components of tear film. Positive statistical correlations were identified between TeaRx diagnostic parameters and widely used benchmark tests for dry eye syndrome
The TeaRx diagnostic tests are developed by DiagnosTear Ltd., one of BioLight’s subsidiaries.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
In this prospective study consisting of approximately 200 subjects, widely-used benchmark tests for dry eye were compared with the TeaRx diagnostic parameters, including Schirmer’s test, TFBUT (Tear-Film Break-Up Time), staining of corneal and conjunctival epithelial cell damage and patient questionnaires. The study analysis was based on testing the sample extremes, quartiles 1 and 4, representing those enrolled subjects with largest differences for each metric.
This approach, BioLight said, resulted in positive statistical correlations that showed many of the predicted trends and correlations between the widely used benchmark tests and the TeaRx diagnostic parameters tests which measure tear film components.
The positive correlation that was identified between certain TeaRx diagnostic parameters and subjective testing standards that are widely used today indicates a unique ability for improving the dry eye syndrome diagnosis by objective quantification of measures over subjective evaluation.
Ms. Suzana Nahum-Zilberberg, BioLight’s CEO said, “Our TeaRx technology’s unique approach has the potential to solve the unmet needs for hundreds of millions of patients suffering from dry eye syndrome. The ability to diagnose this complex multi-faceted syndrome, using a point-of-care multi-parameter test which is more evidence-based, is a novel approach, which is aimed to improve the diagnosis and treatment of a large and growing patient population world-wide. In addition, this test has the potential to identify sub-groups of dry eye syndrome patients which could lead to the development of new therapies to treat the syndrome, as well as additional companion diagnostic tools.”
The trial results are expected in Q2 2015 and should enable the company to specifically define the combination of parameters to be part of a commercially available diagnostic kit and then initiate the regulatory processes for the kit. Assuming the completion of a successful development and regulatory process, BioLight expects to obtain regulatory approvals and launch the multi-parameter test kit in 2016.
